Drug Trial Radar · NCT04896632
Study of Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
64
Actual
Start
May 13, 2021
Primary completion
Nov 24, 2022
Study completion Nov 24, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of single ascending doses and multiple doses of INE963 given orally in healthy participants.
Conditions
- Healthy Volunteers
Interventions
INE 963Drug
Part A: Single ascending dose with 7 planned cohorts\> Part B: multiple dose with 2 planned cohort q24x3 days
PlaceboOther
Part A: single ascending dose with 7 planned cohorts. Part B: multiple dose with 2 planned q24x3 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects with Significant Clinical Safety Labs, reporting SAEs and AEs and ECG findingsTime frame: Dose escalation (21 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Mere Way, Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.